# SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

> **NCT02798744** · PHASE4 · COMPLETED · sponsor: **University of Leicester** · enrollment: 68 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin
- **BEHAVIORAL:** Diet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02798744
- **Lead sponsor:** University of Leicester
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-07-30
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02798744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02798744, "SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02798744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*